文献速递消化系统肿瘤

NOTCH1驱动肝细胞癌中的性别二态性免疫应答

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma.
PubMed 文献 · Cancer Discov · 2025-01-01

肝细胞癌在男性中发病率是女性的两到三倍,但性别对免疫治疗应答的作用尚不明确。本研究发现NOTCH1在肝细胞癌中引发性别二态性抗肿瘤免疫及对FDA批准免疫治疗的应答差异。携带NOTCH1驱动肿瘤的雄性小鼠抗肿瘤免疫应答增强,由树突状细胞和T细胞介导;雌性小鼠则通过树突状细胞介导的CD8+ T细胞启动和激活缺陷出现免疫逃逸和免疫治疗耐药,CD40激动可治疗性恢复。机制上,性别二态性免疫由性染色体基因而非性激素介导。

要点

  • NOTCH1驱动肝细胞癌性别二态性抗肿瘤免疫和对免疫治疗的应答。
  • 雄性小鼠中NOTCH1驱动肿瘤增强抗肿瘤免疫,由树突状细胞和T细胞介导。
  • 雌性小鼠中NOTCH1驱动肿瘤通过树突状细胞-CD8+ T细胞轴缺陷导致免疫逃逸,CD40激动可逆转。

核心结论

  • NOTCH1与性别在肿瘤免疫中存在意想不到的关联,CD40激动恢复树突状细胞-CD8+ T细胞轴可能改善预后。

研究设计与样本

  • 研究采用新型肝细胞癌小鼠模型并在肝细胞癌患者中验证。

主要发现

  • 携带NOTCH1驱动肿瘤的雄性小鼠显示增强的抗肿瘤免疫应答,在小鼠中由树突状细胞和T细胞介导。
  • 携带NOTCH1驱动肿瘤的雌性小鼠通过树突状细胞介导的CD8+ T细胞启动和激活缺陷出现免疫逃逸和对免疫治疗的耐药,CD40激动可治疗性恢复。
  • 性别二态性免疫由性染色体基因而非性激素介导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma presents strong sexual dimorphism, being two to three times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an understudied oncogene in HCC, elicits sexually dimorphic antitumor immunity and response to FDA-approved immunotherapies. Surprisingly, males harboring NOTCH1-driven tumors displayed enhanced antitumor immune responses, which, in mice, were mediated by dendritic and T cells. Conversely, females harboring NOTCH1-driven tumors presented immune evasion and resistance to immunotherapies through a defect in dendritic cell (DC)-mediated priming and activation of CD8+ T cells in mice, which was restored therapeutically with CD40 agonism. Mechanistically, the sexually dimorphic immunity was mediated by genes in the sex chromosomes but not by sex hormones. Together, our study unravels an unexpected association between NOTCH1 and sex in cancer immunity and highlights the potential of restoring the DC-CD8+ T-cell axis with CD40 agonism to improve outcomes. Significance: Although HCC presents strong sexual dimorphism, the role of sex in response to immunotherapies remains elusive. With a novel HCC mouse model and validation in patients with HCC, we demonstrate that NOTCH1 disrupts antitumor immunity specifically in females through a mechanism mediated by sex chromosome genes, which is reversed with CD40 agonism. See related commentary by Zhu and Koltsova, p. 452.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Lindblad KE, Donne R, Liebling I, et al. NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma. Cancer Discov. 2025. PMID: 39560425. doi:10.1158/2159-8290.CD-24-1215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。